玖玖资源网站,爆乳久久久,日韩精品乱码久久久蜜桃,精品呦国产一区二区三区,国产伦高清一区二区三区,sese一区二区,午夜精品福利一区二区三区,三级黄色网站久久免费

首頁
訂購/客服:400-666-5481

PLX8394

    
≥98%

PLX8394

源葉(MedMol)
S88843 一鍵復(fù)制產(chǎn)品信息
1393466-87-9
C25H21F3N6O3S
542.5328496
貨號 規(guī)格 價格 上海 北京 武漢 南京 購買數(shù)量
S88843-2mg
≥98% ¥340.00 貨期:2-3天 - - -
S88843-5mg
98.6% ¥544.00 1 - - -
S88843-10mg
98.6% ¥952.00 5 - - -
S88843-25mg
≥98% ¥1768.00 貨期:2-3天 - - -
S88843-50mg
≥98% ¥2650.00 貨期:2-3天 - - -
S88843-100mg
≥98% ¥3900.00 貨期:2-3天 - - -
產(chǎn)品介紹 參考文獻(xiàn) 質(zhì)檢證書(COA) 摩爾濃度計算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, then inhibit the proliferation of tumor cells which express mutated forms of BRAF. PLX8394 appears to be effective against tumors that express multiple mutated forms of the kinase and may be an effective therapeutic agent for tumors that are resistant to other BRAF inhibitor therapies that are specific for the BRAF V600E mutant

產(chǎn)品描述: PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, then inhibit the proliferation of tumor cells which express mutated forms of BRAF. PLX8394 appears to be effective against tumors that express multiple mutated forms of the kinase and may be an effective therapeutic agent for tumors that are resistant to other BRAF inhibitor therapies that are specific for the BRAF V600E mutant
靶點: Raf
體外研究: PLX8394 (>25 nM) effectively inhibits phosphorylation of ERK1/2 in PRT 3 and PRT 4 cells and in addition to parental cells at 10 nM. PLX8394 effectively reduces phosphorylation of retinoblastoma protein, cyclin D3/D1, and expression of cyclin A2 in parental cells and PRT 3/4 cells. PLX8394 inhibits ERK1/2 phosphorylation and the growth of vemurafenib-resistant cells harboring either a BRAF V600K/L505H double mutation or a transposon-induced, N-terminal truncated form of BRAF. PLX8394 significantly impairs tumor cell growth and suppresses MAPK signaling in LA cell lines expressing either endogenous V600E or non-V600 mutant forms of BRAF
體內(nèi)研究: In mice H1755 xenograft tumors, PLX8394 (150 mg/kg/day) substantially suppresses tumor growth, tumor cell proliferation and MAPK pathway signaling without overt toxicity. PLX8394 combines with erlotinib yields plasma erlotinib concentrations of >1 μM
細(xì)胞實驗: Dissolvent: DMSO. For MTT assays, 2×103?cells are seeded in triplicate in 96 wells in their regular culture medium (containing PLX4720 for PRT lines). Next day, cells are washed twice with PBS and then the medium is replenished containing the indicated RAF inhibitor. Medium is changed 48 hours later and after a further 48 hours, 10 μL of 5 mg/mL MTT reagent is added to wells and incubated for three hours. Formazan crystals are then solubilized overnight with a 1:10 dilution of 0.1 M glycine (pH 10.5) in DMSO. Wells are then analyzed at 450 nM in a Multiskan Spectrum spectrophotometer. Results depicted are normalized to DMSO conditions and are a composite of three independent experiments. Error bars shown are representative of the standard error of mean (SEM).
動物實驗: PLX8394 is dissolved in PEG 400 [20% (v/v)], TPGS [5% (v/v)], and water [75% (v/v)].H1755 tumor xenografts are generated by injection of 5×106 cells in a 50/50 mixture for matrigel and PBS into 6- to 8-wk-old female NOD/SCID mice. Mice are randomized to treatment groups once tumors reach an average size of 150 mm3. H1755 cells are s.c. implanted and allowed to grow to appr 200 mm3 (4 wk after implantation). Mice are then treated with vehicle, vemurafenib, or PLX8394 for 15 d. The vehicle for daily oral gavage is PEG 400 [20% (vol/vol)], tocopheryl polyethylene glycol succinate (TPGS) [5% (vol/vol)], water [75% (vol/vol)]. PLX8394 is dissolved in PEG 400 [20% (vol/vol)], TPGS [5% (vol/vol)], and water [75% (vol/vol)] and vortexed continuously throughout the dosing period. PLX8394 (p.o.) is given at a dose of 150 mg/kg/d
參考文獻(xiàn): 1. Okimoto RA, et al. PreClinicalal efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. 2. Basile KJ, et al. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014 May;27(3):479-484.
溶解性: Soluble  in  DMSO
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 1.843 ml 9.216 ml 18.432 ml
5 mM 0.369 ml 1.843 ml 3.686 ml
10 mM 0.184 ml 0.922 ml 1.843 ml
50 mM 0.037 ml 0.184 ml 0.369 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。

參考文獻(xiàn)

質(zhì)檢證書(COA)

如何獲取質(zhì)檢證書(COA)?
請輸入貨號和一個與之匹配的批號。
例如:
批號:JS298415 貨號:S20001-25g
在貨品標(biāo)簽上如何找到貨號和批號?

摩爾濃度計算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×
主站蜘蛛池模板: 凤凰县| 安宁市| 庐江县| 宝清县| 鄂托克前旗| 大庆市| 丰城市| 新泰市| 嘉黎县| 邛崃市| 贵溪市| 仲巴县| 抚州市| 沙田区| 涟水县| 高台县| 南城县| 桂阳县| 剑阁县| 南岸区| 留坝县| 河东区| 宜宾市| 余江县| 南和县| 喀什市| 铜梁县| 南陵县| 万全县| 临邑县| 盐山县| 梨树县| 信宜市| 东乌珠穆沁旗| 巴马| 永登县| 南木林县| 保亭| 成武县| 老河口市| 上饶县|